Single-shot immunization with recombinant adenovirus encoding vaccinia virus glycoprotein A27L is protective against a virulent respiratory poxvirus infection.

Vaccine
Rajeev Rudraraju, Alistair J Ramsay

Abstract

Significant safety issues have emerged concerning the general use of DRYVAX vaccine. Vaccination with replication-defective recombinant adenovirus (rAd) vaccines may offer a safer and effective alternative to live vaccinia virus (VV) vaccination. Six individual poxvirus glycoproteins: A33R, A34R, A36R, B5R, A27L or L1R that are normally expressed on the surface of infectious vaccinia virus were encoded in rAd vaccines and tested in mice in this study. A single-shot intramuscular injection of rAd encoding A27L protected mice against a lethal intranasal challenge with VV at 4 weeks post-vaccination. By 10 weeks post-vaccination, a significant decrease in post-challenge morbidity was observed that correlated with potent neutralizing antibody responses and the emergence of specific polyfunctional T cell responses. The immunogenicity and protective efficacy of rAd-A27L immunization persisted for at least 35 weeks post-vaccination. This study is the first demonstration that a single-shot subunit vaccine encoding a poxvirus protein confers protection against the mortality and morbidity associated with poxvirus infection.

References

Oct 1, 1980·The Journal of Infectious Diseases·P F Wehrle
Aug 1, 1997·Immunology and Cell Biology·A J RamsayG L Ada
Dec 3, 1999·Immunological Reviews·A J RamsayI A Ramshaw
Mar 22, 2002·Nature Reviews. Immunology·J A BerzofskyI M Belyakov
Jul 12, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Vincent A FulginitiD A Henderson
Apr 14, 2004·Journal of Virology·J W HooperP B Jahrling
May 4, 2004·Methods : a Companion to Methods in Enzymology·Andrea Amalfitano
Dec 8, 2005·JAMA : the Journal of the American Medical Association·Christine G CaseyGina Mootrey
Feb 20, 2008·Reviews in Medical Virology·Andrew W Artenstein
Mar 8, 2008·Nature Reviews. Immunology·Robert A SederMario Roederer
Jun 16, 2009·Current Opinion in Immunology·Richard B KennedyGregory A Poland

❮ Previous
Next ❯

Citations

Aug 3, 2011·Expert Review of Vaccines·Joseph W Golden, Jay W Hooper
Apr 16, 2015·PloS One·Osmarie MartínezMiguel Otero
Jul 16, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·D Huw DaviesXiaowu Liang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.